2023-02-13 16:10:59 admin 1
The company makes full use of the information, technology and talent advantages of China and the United States to develop innovative bispecific antibody drugs for blood cancer, multiple myeloma, triple negative breast cancer and liver cancer. Many projects have the characteristics of long-term, low toxicity, and high-yield technological innovation, and are all updated products of international benchmark products. The company's first leukemia bispecific antibody product has passed the pilot test, is undergoing animal safety evaluation, and has obtained the relevant product patent certificate. It is about to launch the first phase of clinical and industrial application.